ALNY250516P155000
- 0.75
- 0.000.00%
Alnylam Pharmaceuticals Newsroom
Evercore Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $280
Evercore ISI Keeps Their Buy Rating on Alnylam Pharma (ALNY)
BMO Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Announces Target Price $500
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $287 to $371
Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $325
Alnylam Pharmaceuticals Analyst Ratings
Research Alert: Alny Q1 Results Point To A Strong Start To The Year; Guidance Maintained
BMO Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $330
Jefferies Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $329
TD Cowen Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $371
TD Cowen Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $371
TD Cowen Keeps Their Buy Rating on Alnylam Pharma (ALNY)
BofA Securities Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $328
BofA Securities Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $328
Evercore Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $280
Morgan Stanley Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Cuts Target Price to $268
Alnylam Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Needham Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $320